[Clinical features and treatment outcome of extranodal nasal-type NK/T-cell lymphoma of the extra-upper aerodigestive tract].

Autor:	Zhao YT; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China., Wang Y; Department of Radiation Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Hospital, Chongqing 400030, China., Qi SN; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China., Yang Y; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China., He X; Department of Radiation Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing 210009, China., Zhang YJ; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China., Huang HQ; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China., Zhang LL; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China., Wu G; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China., Qu BL; Department of Radiation Oncology, The General Hospital of Chinese People's Liberation Army, Beijing 100853, China., Qian LT; Department of Radiation Oncology, The Affiliated Provincial Hospital of Anhui Medical University, Hefei 230001, China., Hou XR; Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing 100730, China., Zhang FQ; Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing 100730, China., Qiao XY; Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China., Wang H; Department of Radiation Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang 330029, China., Li GF; Department of Radiation Oncology, Beijing Hospital, National Geriatric Medical Center, Beijing 100730, China., Zhu Y; Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China., Cao JZ; Department of Radiation Oncology, Shanxi Cancer Hospital and the Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan 030013, China., Wu JX; Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Fuzhou 350014, China., Wu T; Department of Radiation Lymphoma, Affiliated Hospital of Guizhou Medical University, Guizhou Cancer Hospital, Guiyang 550001, China., Zhu SY; Department of Radiation Oncology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha 410013, China., Shi M; Department of Radiation Oncology, Xijing Hospital of Fourth Military Medical University, Xi'an 710032, China., Xu LM; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin 300060, China., Yuan ZY; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin 300060, China., Su H; Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing 100071, China., Song YQ; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China., Zhu J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China., Li YX; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Jazyk:	čínština
Zdroj:	Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2021 Jul 23; Vol. 43 (7), pp. 787-794.
DOI:	10.3760/cma.j.cn112152-20191207-00789
Abstrakt:	Objective: To investigate the clinical features and prognosis of extranodal nasal-type NK/T-cell lymphoma of the extra-upper aerodigestive tract (extra-UADT NKTCL). Methods: The clinical data of 159 patients with extra-UADT NKTCL from the China Lymphoma Collaborative Group (CLCG) database between November 2001 and December 2015 were retrospectively analyzed. Kaplan-Meier survival analysis and Log-rank test were used to evaluate the prognosis. The Cox regression model is used for multi-factor analysis. Results: Extra-UADT NKTCL commonly occurs in skin and soft tissues (106/159, 66.7%) and gastrointestinal tract (31/159, 19.5%). The incidences of elevated lactate dehydrogenase (LDH) and Ann Arbor Ⅲ~Ⅳ stage were 47.8% (76/159) and 64.2% (102/159), respectively. The 3-year overall survival (OS) and progression-free survival (PFS) rates were 43.6% and 27.9%, respectively. The corresponding OS rates of primary skin/soft tissue site and gastrointestinal tract site were 41.0% and 59.4% ( P =0.281), while the PFS rates were 24.8% and 48.3%, respectively ( P =0.109). Combined modality treatment improved the 3-year OS of all the patients (58.4% vs 33.9%, P =0.001) and 3-year PFS (40.7% vs 20.7%, P =0.008) when compared with chemotherapy alone. LDH elevation, Ann Arbor synthesising and ≥2 junction external bits were intrusive as independent risk factors for total survival ( P <0.05), LDH elevation and ≥2 junction outer bits were intrusive as independent risk factors for progressionless survival( P <0.05). The distant extranodal dissemination was the primary failure patterns. Conclusions: Extra-UADT NKTCL appears to have distinct clinical characteristics and poor outcome. Compared with chemotherapy alone, combined modality treatment may improve the prognosis of patients with extra-UADT NKTCL.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu